The CES news is coming out fast and furious, with ASUS revealing plans to release a Windows 8 ARM tablet in 2012, with what TPCR believes could be a possible launch at CES. In addition, ASUS will show off a new 7-inch tablet, possibly the?glasses-free 3D MeMO, and a 10-inch tablet with a high resolution screen, both likely running Android Ice Cream Sandwich. Rounding out the new ASUS CES tablets will be a 3G Transformer Prime with improved GPS performance.
The news comes out of Taipei, from a pre-CES presentation in which ASUS Eee division head Samon Hu outlined the ASUS 2012 tablet product roadmap. Rumors and rumblings that ASUS would release a Windows 8 ARM tablet and 7-inch tablet circulated earlier this year. TabletPCReview will be in Vegas, and the team will certainly visit with ASUS to get the scoop, and hopefully catch at least a glimpse of the Windows 8 ARM tablet.
But what about the other ASUS products rumored for CES? The Padfone tablet with docking smartphone combo was announced at Computex in September, but hasn?t been seen since. A CES re-introduction might be in order. Finally, Hu mentioned two additional 10-inch tablets slotted for release in 2012, but no further details were provided.
Source: Netbook News
?
Related Articles:
?????? ????????? '); //individual ad placement, modify as needed if (typeof adZoneValue_Holder == "undefined") var adZoneValue_Holder=""; adSize[adTile] = "300x250,300x600"; adType[adTile] = "IMU/HALFPAGE"; if (typeof adSes == "undefined") var adSes = getURLParamValue("ses"); //variable adImuOnly set outside of template to suppress 300x600 if (typeof adImuOnly == "undefined") var adImuOnly = false; if (adImuOnly) { adSize[adTile] = "300x250"; adType[adTile] = "IMU"; } adString[adTile] = ""; adString[adTile] += "ipt>"; //info if (window.location.search.indexOf("adString=on") != -1) tg_adLog += " " + adType[adTile] + " " + " site=" + adSiteValue + " zone=" + adZoneValue + "\n tgp=" + tg_page + " tgpi=" + tg_page_id + " category=" + tg_productCategoryID + " adProduct=" + adProduct + " ses=" + adSes + " kw=" + adKW + " pos=0" + " sz=" + adSize[adTile] + " tile=" + adTile + " ord=" + adRandom; if (adZoneValue_Holder != "") adZoneValue = adZoneValue_Holder; // End Hide -->
New drug screening identifies chemical agents with potent anti-cancer activityPublic release date: 5-Jan-2012 [ | E-mail | Share ]
Contact: Aaron Lohr alohr@endo-society.org 240-482-1380 The Endocrine Society
New study reveals possible opportunities to repurpose drugs for thyroid cancer treatment
Drugs already approved for clinical use across a variety of therapeutic categories can be screened to identify effective agents for thyroid cancer according to a recent study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). These findings could rapidly be implemented into a clinical trial to test how effective the treatment would be.
The discovery of new chemical agents capable of modulating a disease is a long and expensive process. An alternative approach that is just beginning to be explored is the potential repurposing of already established drugs which have been approved for clinical use. The current study examined the newly assembled National Institutes of Health (NIH) Chemical Genomic Center's pharmaceutical collection, which contains 2,816 approved drugs and bioactive compounds and sought to identify agents with an anti-cancer effect in thyroid cancer cell lines.
"To our knowledge, this is the first study to use such a large collection of clinical drugs to test anti-proliferative effect in cancer cells," said Electron Kebebew, MD, of the National Cancer Institute in Bethesda, MD and lead author of the study. "The compounds found to have potent activity in our screen represent possible opportunities to repurpose these drugs for the treatment of patients with aggressive recurrent or metastatic thyroid cancer."
In this study, researchers used a quantitative high-throughput screening (qHTS) approach to examine the effect of 2,816 clinically approved drugs on thyroid cancer cells. qHTS is a titration-based screening paradigm where compounds are screened at multiple concentrations. By employing this approach, researchers found numerous agents across different therapeutic categories and mode of action that had an anti-cancer effect.
"Clinicians can more readily translate these findings into therapy when the drug characteristics are well-known. The drugs can then be used in developing clinical trials or in some cases for off-label use," said Kebebew. "Furthermore, qHTS could be used for identifying therapeutics not only for cancer, but for many other diseases."
###
Other researchers working on the study include Lisa Zhang, Mei He and Naris Nilubol of the National Cancer Institute and Yaqin Zhang and Min Shen of the National Human Genome Research Institute in Bethesda, MD.
The article, "Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: Opportunities for repurposing," appears in the March 2012 issue of JCEM.
Founded in 1916, The Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society's membership consists of over 14,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society and the field of endocrinology, visit our site at https://www.endo-society.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
New drug screening identifies chemical agents with potent anti-cancer activityPublic release date: 5-Jan-2012 [ | E-mail | Share ]
Contact: Aaron Lohr alohr@endo-society.org 240-482-1380 The Endocrine Society
New study reveals possible opportunities to repurpose drugs for thyroid cancer treatment
Drugs already approved for clinical use across a variety of therapeutic categories can be screened to identify effective agents for thyroid cancer according to a recent study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). These findings could rapidly be implemented into a clinical trial to test how effective the treatment would be.
The discovery of new chemical agents capable of modulating a disease is a long and expensive process. An alternative approach that is just beginning to be explored is the potential repurposing of already established drugs which have been approved for clinical use. The current study examined the newly assembled National Institutes of Health (NIH) Chemical Genomic Center's pharmaceutical collection, which contains 2,816 approved drugs and bioactive compounds and sought to identify agents with an anti-cancer effect in thyroid cancer cell lines.
"To our knowledge, this is the first study to use such a large collection of clinical drugs to test anti-proliferative effect in cancer cells," said Electron Kebebew, MD, of the National Cancer Institute in Bethesda, MD and lead author of the study. "The compounds found to have potent activity in our screen represent possible opportunities to repurpose these drugs for the treatment of patients with aggressive recurrent or metastatic thyroid cancer."
In this study, researchers used a quantitative high-throughput screening (qHTS) approach to examine the effect of 2,816 clinically approved drugs on thyroid cancer cells. qHTS is a titration-based screening paradigm where compounds are screened at multiple concentrations. By employing this approach, researchers found numerous agents across different therapeutic categories and mode of action that had an anti-cancer effect.
"Clinicians can more readily translate these findings into therapy when the drug characteristics are well-known. The drugs can then be used in developing clinical trials or in some cases for off-label use," said Kebebew. "Furthermore, qHTS could be used for identifying therapeutics not only for cancer, but for many other diseases."
###
Other researchers working on the study include Lisa Zhang, Mei He and Naris Nilubol of the National Cancer Institute and Yaqin Zhang and Min Shen of the National Human Genome Research Institute in Bethesda, MD.
The article, "Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: Opportunities for repurposing," appears in the March 2012 issue of JCEM.
Founded in 1916, The Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society's membership consists of over 14,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society and the field of endocrinology, visit our site at https://www.endo-society.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Twitter sur votre mobile ? Cliquez ici m.twitter.com!
Passer cette ?tape
Connexion
Connexion
Rejoignez Twitter !
World of NORTHCOM ? After secret U.S. Military visit, Mexico deploys 8,000 troops to Texas border bit.ly/zX1A35Il y a environ 11 heuresvia twitterfeedRetweeted by 4 people
If Ron Paul was disappointed in last night's Iowa caucus results, it didn't show.
The Republican Congressman from Texas finished a strong third behind Mitt Romney and Rick Santorum, but certainly served notice that he's a factor in 2012.
Paul wanted some legitimacy and a bigger platform for his movement, and by securing over 20 percent in the first-in-the-nation caucuses, he's on his way.
On stage before a cheering crowd Tuesday, Paul said winning elections is the best way to promote a cause, and that he was one of three winners last night:
Claiming a ticket out of Iowa, Paul vowed to continue his fight, even as GOP rivals such as Newt Gingrich, Romney and Santorum dismiss him as unelectable.
Iowa voters thought otherwise, taking to Paul’s small-government, anti-war and pro-civil liberties message in enough numbers to lift him into the top tier.
Evangelicals, home schoolers, young people, moderates, libertarians and disaffected Democrats formed an unlikely coalition that led to his strong showing.
Can it be replicated or improved upon elsewhere? That's the key question.
“We have tremendous opportunity," Paul said. "It won’t be long that there’s going to be an election up in New Hampshire, and believe me, this momentum is going to continue, this movement is going to continue and we are going to keep scoring.”
With a huge smile at the end, he continued, “So tonight, we have come out of an election where there were essentially three winners, three top vote-getters."
"We will go on, we will raise the money, I have no doubt about the volunteers.”
Indeed, Paul's fundraising and organization make him formidable almost anywhere. As the field narrows (Michele Bachmann is already out), can he gain support?
Jan. 4 (Bloomberg) -- Google Inc. demoted its Chrome browser in Web-search rankings after an advertising effort for the tool ran afoul of its own rules governing paid promotions.
The company is ?taking manual action to demote? Chrome and lower its ranking for at least 60 days, Mountain View, California-based Google said yesterday in an e-mailed statement.
Google?s remarks came in response to blog posts that made favorable remarks about the Chrome browsing tool and said they were sponsored by Google, said Aaron Wall, founder of SEOBook.com, which trains marketers on how to improve search results. Google said it didn?t give a green light to the campaign, which it said stemmed from efforts to buy online ads.
?We have consistently avoided paid sponsorships, including paying bloggers to promote our products, because these kind of promotions are not transparent or in the best interests of users,? Google said. ?We?re now looking at what changes we need to make to ensure that this never happens again.?
Helping users distinguish between authentic endorsements and advertising is central to what search engines do, and Google has punished websites it accuses of manipulating results to present paid content as original thought.
?People were outraged and cursing about it,? Wall said of online discussion that began last week. ?They were saying it was an insane double standard and crazy.?
Essence Digital, an Internet-advertising company that has worked with Google to promote Chrome, posted a statement online to offer ?context on what happened.?
Essence Digital said that Google didn?t authorize a campaign to pay for sponsored blog posts. Google only agreed to buy online video ads, Essence Digital said. The company apologized to Google.
Matt Isaacs, CEO of Essence Digital, declined to elaborate.
--Editor: Tom Giles
To contact the reporter on this story: Jordan Robertson in San Francisco at jrobertson40@bloomberg.net
To contact the editor responsible for this story: Tom Giles at tgiles5@bloomberg.net
Gary Dobson and David Norris were found guilty of the murder of Stephen Lawrence, above, at the Old Bailey in London on Tuesday.
By NBC News, msnbc.com staff and news services
LONDON - A jury found two men guilty on Tuesday of murdering a black teenager in a brutal assault that shook Britain to its roots nearly 20 years ago.
Gary Dobson, 36, and David Norris, 35, had denied killing Stephen Lawrence, who was attacked by a gang of five youths and stabbed to death in southeast London in 1993.
Prosecutors had claimed that blood, hair and fibers traced to Lawrence were found on Dobson and Norris' clothes, proving their involvement. The defense had claimed the evidence was contaminated.
The jury deliberated for three days at the Old Bailey courthouse before announcing the verdict Tuesday.
The initial charges against three of the five youths in 1993 were dismissed following a mishandling of evidence by police.
Change in criminal law The case has marked a seminal moment in race relations in the UK and has helped modify recent British criminal law.
Crown Prosecution Service / Reuters
Gary Dobson (left) and David Norris (right) had denied killing Stephen Lawrence in 1993.
Two internal police inquiries acknowledged police were not vigorous in pursuing evidence. And a public inquiry, the McPherson Report (1999), led to recommendations in recognizing race-based hate crimes.
The McPherson Report also went a step further in acknowledging that racism was an institutional feature of London's Metropolitan Police and recommended that race relations legislation should not only apply to the public but also to the police force.
Additionally, Britain's double jeopardy law has been revised to allow a suspect to be tried for a second time over the same crime if new evidence comes to light. With the advances of DNA technology, prosecutors were able to call for a review of evidence against Dobson and Norris this year.
More from msnbc.com and NBC News:
NBC News producers Karl Bostic and Jason Jouavel and The Associated Press contributed to this report.
Amsterdam News.Net Monday 2nd January, 2012 (Source: Business Week)
Dec. 31 (Bloomberg) -- The euro had a second consecutive annual loss against the dollar for the first time in a decade as rising yields on the region's sovereign debt reflected speculation about defaults and stalling economic growth. ...
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_uN6-B41Gesg_ig9STGJ4UJh_vF6jYZi0bkzqebU5CicEP77mi-3jLGX5jy_eYKDRZ_YMr9rJYqd-qn9LX3aMa33_ZKiJApVnpUMlO1VBk=s0-d){kind=small}
Public release date: 5-Jan-2012
Share ] 
BlackListedNews 
